Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC

Clinical trial NCT07674524 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07674524
Sponsor: Sun Yat-sen University
Status: NOT_YET_RECRUITING
Study type: OBSERVATIONAL

Non-Small Cell Lung Cancer (NSCLC)Hyperlipidemia ALK Gene Mutation ALK-positive

Start date: 2026-08-01
Primary completion: 2029-12-31
Enrollment: 160

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.